...
vrtx-img

Vertex Pharmaceuticals Inc, Common Stock

VRTX

NSQ

$446.5

-$22.74

(-4.85%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$120.55B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.74M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$391.01 L
$519.88 H
$446.5

About Vertex Pharmaceuticals Inc, Common Stock

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVRTXSectorS&P500
1-Week Return-4.44%-2.06%-0.55%
1-Month Return-4.18%-1.92%2.72%
3-Month Return-5.62%-10.4%7.66%
6-Month Return-4.23%-4.6%10.15%
1-Year Return10.59%4.06%27.53%
3-Year Return107.74%1.94%32.31%
5-Year Return104.01%36.48%89.2%
10-Year Return280.07%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue4.16B6.21B7.57B8.93B9.87B[{"date":"2019-12-31","value":42.18,"profit":true},{"date":"2020-12-31","value":62.88,"profit":true},{"date":"2021-12-31","value":76.75,"profit":true},{"date":"2022-12-31","value":90.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue547.76M736.30M904.20M1.08B1.26B[{"date":"2019-12-31","value":43.4,"profit":true},{"date":"2020-12-31","value":58.33,"profit":true},{"date":"2021-12-31","value":71.64,"profit":true},{"date":"2022-12-31","value":85.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit3.62B5.47B6.67B7.85B8.61B[{"date":"2019-12-31","value":42,"profit":true},{"date":"2020-12-31","value":63.55,"profit":true},{"date":"2021-12-31","value":77.5,"profit":true},{"date":"2022-12-31","value":91.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin86.84%88.14%88.06%87.90%87.21%[{"date":"2019-12-31","value":98.53,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.92,"profit":true},{"date":"2022-12-31","value":99.74,"profit":true},{"date":"2023-12-31","value":98.95,"profit":true}]
Operating Expenses2.41B2.60B3.89B3.48B4.78B[{"date":"2019-12-31","value":50.53,"profit":true},{"date":"2020-12-31","value":54.45,"profit":true},{"date":"2021-12-31","value":81.49,"profit":true},{"date":"2022-12-31","value":72.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income1.20B2.86B2.78B4.31B4.31B[{"date":"2019-12-31","value":27.8,"profit":true},{"date":"2020-12-31","value":66.31,"profit":true},{"date":"2021-12-31","value":64.59,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense202.53M26.89M(108.30M)14.80M642.90M[{"date":"2019-12-31","value":31.5,"profit":true},{"date":"2020-12-31","value":4.18,"profit":true},{"date":"2021-12-31","value":-16.85,"profit":false},{"date":"2022-12-31","value":2.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income1.39B3.12B2.73B4.23B4.38B[{"date":"2019-12-31","value":31.85,"profit":true},{"date":"2020-12-31","value":71.16,"profit":true},{"date":"2021-12-31","value":62.34,"profit":true},{"date":"2022-12-31","value":96.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes218.11M405.15M388.30M910.40M760.20M[{"date":"2019-12-31","value":23.96,"profit":true},{"date":"2020-12-31","value":44.5,"profit":true},{"date":"2021-12-31","value":42.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.5,"profit":true}]
Income After Taxes1.18B2.71B2.34B3.32B3.62B[{"date":"2019-12-31","value":32.51,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations1.18B2.71B2.34B3.32B3.62B[{"date":"2019-12-31","value":32.51,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income1.18B2.71B2.34B3.32B3.62B[{"date":"2019-12-31","value":32.51,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)5.3310.3213.0214.8915.22[{"date":"2019-12-31","value":35.02,"profit":true},{"date":"2020-12-31","value":67.81,"profit":true},{"date":"2021-12-31","value":85.55,"profit":true},{"date":"2022-12-31","value":97.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VRTX
Cash Ratio 1.64
Current Ratio 2.47
Quick Ratio 2.20

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VRTX
ROA (LTM) 12.05%
ROE (LTM) -2.98%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VRTX
Debt Ratio Lower is generally better. Negative is bad. 0.30
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.70

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VRTX
Trailing PE NM
Forward PE 25.45
P/S (TTM) 11.34
P/B 7.71
Price/FCF 96
EV/R 10.89
EV/Ebitda 223.54
PEG 1.23

FAQs

What is Vertex Pharmaceuticals Inc share price today?

Vertex Pharmaceuticals Inc (VRTX) share price today is $446.5

Can Indians buy Vertex Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Vertex Pharmaceuticals Inc (VRTX) on Vested. To buy Vertex Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Vertex Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Vertex Pharmaceuticals Inc (VRTX) via the Vested app. You can start investing in Vertex Pharmaceuticals Inc (VRTX) with a minimum investment of $1.

How to invest in Vertex Pharmaceuticals Inc shares from India?

You can invest in shares of Vertex Pharmaceuticals Inc (VRTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in VRTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Vertex Pharmaceuticals Inc shares
What is Vertex Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Vertex Pharmaceuticals Inc (VRTX) is $519.88. The 52-week low price of Vertex Pharmaceuticals Inc (VRTX) is $391.01.

What is Vertex Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Vertex Pharmaceuticals Inc (VRTX) is

What is Vertex Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Vertex Pharmaceuticals Inc (VRTX) is 7.71

What is Vertex Pharmaceuticals Inc dividend yield?

The dividend yield of Vertex Pharmaceuticals Inc (VRTX) is 0.00%

What is the Market Cap of Vertex Pharmaceuticals Inc?

The market capitalization of Vertex Pharmaceuticals Inc (VRTX) is $120.55B

What is Vertex Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Vertex Pharmaceuticals Inc is VRTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top